Given the potential for CD96-targeted mAb therapy in myeloid neoplasms, especially the capability to specifically target AML LSCs, it is surprising that no clinical trials of anti-CD96 therapy have yet been reported. This evidence concerns the gene CD96 and acute myeloid leukemia.